Clinical Trial

Chronic Subdural Hematoma Treatment With Intra-Arterial Bevacizumab Injection

Study acronym: CHAI
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to test whether infusing bevacizumab into the middle meningeal arteries can be used to treat chronic subdural hematomas (cSDH). The main questions it aims to answer are: * Is bevacizumab infusion safe in cSDH patients? * Is bevacizumab infusion effective in treating cSDH?
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-07-14; most recent amendment 2025-06-25.
Trial Details
NCT Number NCT06510582
Lead Sponsor The Cooper Health System
Collaborators: Society of Vascular and Interventional Neurology
Conditions Chronic Subdural Hematoma
Enrollment 140 participants
Start Date 2024-06-17
Primary Completion 2028-06 (estimated)
Study Completion 2028-06 (estimated)
Updated on ClinicalTrials.gov 2025-07-01